TxCell and Ospedale San Raffaele Launch Collaboration for the Development of CAR-Tregs in Lupus Nephritis TxCell SA and Ospedale San Raffaele announced they have entered into a strategic R&D collaboration. The collaboration will include a development arm focused on Lupus Nephritis, as well as a research program dedicated to CAR-Treg biology. [TxCell SA] Press Release FDA Awards $2.25M Grant to Study Immunosuppresive Drug in High-Risk Patients Rita Alloway, PharmD, University of Cincinnati (UC) research professor of medicine and director of transplant clinical research within the UC Department of Internal Medicine, received a $2.25 million FDA grant to run two clinical trials studying the effects of immunosuppressant tacrolimus (Prograf and generics) in high-risk transplant patients. [University of Cincinnati] Press Release Researcher Receives NIH Grant to Continue Development of New Therapeutic Agents for Multiple Sclerosis, Cancer and Sepsis A leading scientist at Florida Atlantic University has received $540,250 from the National Cancer Institute of the National Institutes of Health (NIH) to continue his groundbreaking research to develop new therapeutic agents for collagen-based diseases including multiple sclerosis, cancer and sepsis. [Florida Atlantic University] Press Release Research in Liver Cancer, Tissue Regeneration at Children’s Research Institute at UTSW Garners Stand Up to Cancer Grant Dr. Hao Zhu, Assistant Professor of Children’s Medical Center Research Institute at UT Southwestern, is one of ten researchers in the nation to receive a Stand Up To Cancer grant to further his studies of a gene whose absence protects mice against liver cancer and promotes liver tissue regeneration in mammals. [The University of Texas Southwestern Medical Center] Press Release NanoCor Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) for Carfostin® NanoCor Therapeutics, Inc. announced that the United States Food and Drug Administration (FDA) has accepted the company’s IND application for Carfostin®, a cardiac gene therapy in development for the treatment of congestive heart failure. [NanoCor Therapeutics, Inc. (PR Newswire Association LLC)] Press Release FDA Grants Orphan Drug Exclusivity to EVOMELA™ (Melphalan) for Injection, Indicated for Multiple Myeloma Spectrum Pharmaceuticals announced that the U.S. Food and Drug Administration Office of Orphan Products Development has granted seven years of Orphan Drug Exclusivity for EVOMELA for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. [Spectrum Pharmaceuticals] Press Release Diplomat to Dispense VENCLEXTA™ for the Treatment of Chronic Lymphocytic Leukemia Diplomat Pharmacy, Inc. announced that it is now filling prescriptions for VENCLEXTA™ (venetoclax). VENCLEXTA™ was recently approved by the U.S. Food and Drug Administration for the treatment of people with chronic lymphocytic leukemia who have received at least one prior therapy, including those with 17p deletion. [Diplomat Pharmacy, Inc.] Press Release RXi Pharmaceuticals Fortifies Its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109 RXi Pharmaceuticals Corporation announced that it has received a Notice of Allowance, from the United States Patent and Trademark Office, for both the composition of matter and methods of use for its self-delivering RNAi (sd-rxRNA®) compounds targeting connective tissue growth factor. [RXi Pharmaceuticals Corporation] Press Release Creative Medical Health, Inc. Files Patent on Stem Cell Therapy for Zika Virus Neurological Effects Creative Medical Health, Inc. (CMH) announced filing of a patent covering the use of proprietary mesenchymal stem cell types in the treatment of neurological complications of Zika virus. The patent is a continuation of ongoing research at CMH that previously led to filing of intellectual property covering use of mesenchymal stem cells for multiple sclerosis. [Creative Medical Health, Inc. (Business Wire)] Press Release SpinalCyte, LLC Receives New Canadian Patent for Spinal Disc Tissue Engineering SpinalCyte, LLC announced the issuance of Canadian Patent No. 2641170, “Methods and Compositions for Repair of Cartilage Using an In Vivo Bioreactor.” [SpinalCyte, LLC] Press Release |